{"id":"simponi-golimumab","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to TNF-alpha, Golimumab prevents it from interacting with its receptor on cell surfaces, thereby reducing inflammation and halting disease progression in various conditions. This mechanism of action is central to its therapeutic effects in treating autoimmune diseases.","oneSentence":"Simponi (Golimumab) is a monoclonal antibody that selectively binds to and inhibits tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:34:43.241Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid Arthritis"},{"name":"Psoriatic Arthritis"},{"name":"Ulcerative Colitis"}]},"trialDetails":[{"nctId":"NCT07495644","phase":"","title":"Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt","status":"NOT_YET_RECRUITING","sponsor":"Assiut University","startDate":"2026-03-01","conditions":"Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)","enrollment":95},{"nctId":"NCT05242484","phase":"PHASE2","title":"A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-09-19","conditions":"Colitis, Ulcerative","enrollment":577},{"nctId":"NCT03596645","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-10-29","conditions":"Colitis, Ulcerative","enrollment":84},{"nctId":"NCT05071664","phase":"PHASE2","title":"A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-10-25","conditions":"Arthritis, Psoriatic","enrollment":91},{"nctId":"NCT02808780","phase":"","title":"An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Biotech, Inc.","startDate":"2016-12-16","conditions":"Ulcerative Colitis","enrollment":537},{"nctId":"NCT05960578","phase":"PHASE2","title":"Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2024-05-23","conditions":"Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":8},{"nctId":"NCT07177209","phase":"","title":"Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-02-27","conditions":"Ulcerative Colitis","enrollment":4000},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT04259138","phase":"PHASE4","title":"Determination of the Optimal Treatment Target in Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2020-02-18","conditions":"Colitis, Ulcerative","enrollment":672},{"nctId":"NCT05242471","phase":"PHASE2","title":"A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-22","conditions":"Crohn's Disease","enrollment":703},{"nctId":"NCT04108468","phase":"PHASE3","title":"GOLimumab and Methotrexate Versus Methotrexate in Very Early PsA","status":"COMPLETED","sponsor":"The Leeds Teaching Hospitals NHS Trust","startDate":"2015-10-27","conditions":"Psoriatic Arthritis","enrollment":84},{"nctId":"NCT02277444","phase":"PHASE3","title":"A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-12-22","conditions":"Arthritis, Juvenile","enrollment":130},{"nctId":"NCT02186873","phase":"PHASE3","title":"A Study of Golimumab in Participants With Active Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2014-09-03","conditions":"Ankylosing Spondylitis","enrollment":208},{"nctId":"NCT05669833","phase":"PHASE3","title":"Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2023-07-14","conditions":"Psoriatic Arthritis","enrollment":63},{"nctId":"NCT05379322","phase":"PHASE3","title":"The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients","status":"WITHDRAWN","sponsor":"Abu Dhabi Stem Cells Center","startDate":"2023-03-01","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT04435288","phase":"PHASE3","title":"Spondyloarthritis: Inducing Drug-free Remission by Early TNF-alpha Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2020-08-24","conditions":"Peripheral Spondyloarthritis","enrollment":90},{"nctId":"NCT07149792","phase":"PHASE4","title":"A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2025-07-29","conditions":"Psoriasis, Psoriasis Arthritis, Biologics","enrollment":50},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT04997733","phase":"PHASE3","title":"Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-22","conditions":"Crohn Disease","enrollment":150},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT04891640","phase":"NA","title":"Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-11-11","conditions":"Juvenile Spondyloarthritis","enrollment":164},{"nctId":"NCT01081717","phase":"","title":"Golimumab Safety and Surveillance Program Using the Ingenix NHI Database","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-04-14","conditions":"Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing Spondylitis","enrollment":1064},{"nctId":"NCT03011268","phase":"NA","title":"Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?","status":"COMPLETED","sponsor":"Helse Møre og Romsdal HF","startDate":"2017-06-09","conditions":"Colitis,Ulcerative","enrollment":174},{"nctId":"NCT05632211","phase":"PHASE1","title":"A Study to Investigate the PK, Safety, and Tolerability Between AVT05, US and EU Simponi® in Healthy Adult Participants","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2022-12-16","conditions":"Healthy Adult Subjects","enrollment":336},{"nctId":"NCT05080218","phase":"PHASE4","title":"COVID-19 VaccinE Response in Rheumatology Patients","status":"COMPLETED","sponsor":"Jeffrey Curtis","startDate":"2021-11-15","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis","enrollment":841},{"nctId":"NCT02438787","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-31","conditions":"Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT02437162","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-03","conditions":"Axial Spondyloarthritis","enrollment":347},{"nctId":"NCT04571697","phase":"","title":"A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-28","conditions":"Dementia, Alzheimer Disease","enrollment":34647},{"nctId":"NCT00741793","phase":"","title":"Biologic Treatment Registry Across Canada","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2002-02-12","conditions":"Arthritis, Rheumatoid, Spondyloarthritis, Axial, Arthritis, Psoriatic","enrollment":2821},{"nctId":"NCT05313620","phase":"PHASE4","title":"Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events","status":"RECRUITING","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2022-04-01","conditions":"Ulcerative Colitis, Thromboembolism","enrollment":30},{"nctId":"NCT03885713","phase":"PHASE4","title":"Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2019-09-10","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":180},{"nctId":"NCT06089590","phase":"","title":"Ibd CAncer and seRious Infections in France (I-CARE 2)","status":"RECRUITING","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2024-01-25","conditions":"IBD, Ulcerative Colitis, Crohn Disease","enrollment":6000},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT03591770","phase":"PHASE4","title":"Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-07-31","conditions":"Inflammatory Bowel Diseases","enrollment":15},{"nctId":"NCT03270501","phase":"PHASE3","title":"Efficacy of Golimumab in Early Axial Spondyloarthritis in Relation to Gut Inflammation","status":"COMPLETED","sponsor":"University Ghent","startDate":"2017-11-08","conditions":"Axial Spondyloarthritis","enrollment":64},{"nctId":"NCT03733925","phase":"PHASE4","title":"A Study of Golimumab in the Treatment of Indian Participants With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis","status":"COMPLETED","sponsor":"Johnson & Johnson Private Limited","startDate":"2019-01-07","conditions":"Spondylitis, Ankylosing, Arthritis, Psoriatic","enrollment":100},{"nctId":"NCT02846545","phase":"PHASE2","title":"A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-08-26","conditions":"Diabetes Mellitus, Type 1","enrollment":84},{"nctId":"NCT01804166","phase":"PHASE4","title":"A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2013-03-21","conditions":"Hepatosplenic T-Cell Lymphoma","enrollment":1},{"nctId":"NCT03298542","phase":"PHASE1","title":"A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-10-16","conditions":"Pre-Symptomatic Type 1 Diabetes","enrollment":8},{"nctId":"NCT01848028","phase":"","title":"PsoBest - The German Psoriasis Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-01","conditions":"Psoriasis, Psoriatic-arthritis","enrollment":3500},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT02674308","phase":"","title":"Entyvio (Vedolizumab) Long Term Safety Study","status":"COMPLETED","sponsor":"Takeda","startDate":"2015-03-24","conditions":"Ulcerative Colitis and Crohn's Disease","enrollment":5302},{"nctId":"NCT05842213","phase":"PHASE3","title":"Comparative, Multicenter Study in Subjects with Rheumatoid Arthritis, ALVOFLEX","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2023-03-30","conditions":"Rheumatoid Arthritis","enrollment":502},{"nctId":"NCT06126835","phase":"","title":"A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Ulcerative Colitis and Their Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2024-08-26","conditions":"Ulcerative Colitis","enrollment":2828},{"nctId":"NCT03557853","phase":"","title":"Clinical and Radiological Manifestations of Coxitis in Patients With Ankylosing Spondylitis Treated With Golimumab","status":"COMPLETED","sponsor":"MSD Pharmaceuticals LLC","startDate":"2016-06","conditions":"Ankylosing Spondylitis, Coxitis","enrollment":39},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT04156984","phase":"PHASE4","title":"Comparison of Two Different Golimumab Dosing Regimens for Ulcerative Colitis","status":"COMPLETED","sponsor":"David Drobne","startDate":"2021-04-07","conditions":"Ulcerative Colitis","enrollment":27},{"nctId":"NCT03729349","phase":"","title":"Golimumab for Adherence in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Janssen Inc.","startDate":"2019-01-15","conditions":"Arthritis, Rheumatoid","enrollment":222},{"nctId":"NCT02914717","phase":"","title":"The Belgian SMART Study Evaluating the Use of Golimumab for Ulcerative Colitis","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-04-27","conditions":"Ulcerative Colitis","enrollment":100},{"nctId":"NCT03710486","phase":"","title":"A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2019-02-19","conditions":"Colitis, Ulcerative, Crohn Disease","enrollment":409},{"nctId":"NCT01965132","phase":"","title":"Korean College of Rheumatology Biologics and Targeted Therapy Registry","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2012-12-01","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":10000},{"nctId":"NCT04152759","phase":"PHASE1","title":"Comparative Study to Evaluate the Pharmacokinetics of BAT2506 vs Simponi® in Healthy Subjects","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2019-09-09","conditions":"Psoriatic Arthritis","enrollment":182},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15},{"nctId":"NCT03662542","phase":"PHASE2","title":"A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-11-20","conditions":"Colitis, Ulcerative","enrollment":214},{"nctId":"NCT05702879","phase":"","title":"Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success","status":"UNKNOWN","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-09-06","conditions":"Ulcerative Colitis","enrollment":240},{"nctId":"NCT05046431","phase":"PHASE3","title":"Comparative Study of BAT2506 With Simponi® in Participants With Active Psoriatic Arthritis","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2021-05-06","conditions":"Psoriatic Arthritis","enrollment":704},{"nctId":"NCT05332730","phase":"PHASE1","title":"A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®","status":"COMPLETED","sponsor":"Bio-Thera Solutions","startDate":"2022-08-01","conditions":"Psoriatic Arthritis","enrollment":375},{"nctId":"NCT03253796","phase":"PHASE4","title":"Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-11-07","conditions":"Spondyloarthritis","enrollment":323},{"nctId":"NCT02425865","phase":"PHASE4","title":"Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET","status":"COMPLETED","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2016-12","conditions":"ULCERATIVE COLITIS","enrollment":202},{"nctId":"NCT01900574","phase":"PHASE1","title":"A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-08-09","conditions":"Colitis, Ulcerative","enrollment":35},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT03945903","phase":"","title":"Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults","status":"NO_LONGER_AVAILABLE","sponsor":"Janssen Research & Development, LLC","startDate":"","conditions":"Diabetes Mellitus, Type 1","enrollment":""},{"nctId":"NCT04218565","phase":"PHASE2","title":"Golimumab for the Treatment of Refractory Behcet's Uveitis","status":"TERMINATED","sponsor":"Wenjie Zheng","startDate":"2020-02-15","conditions":"Behcet Syndrome, Uveitis","enrollment":1},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT05567380","phase":"","title":"Comparative Study of Janus Kinase (JAK) Inhibitors Vs Tumor Necrosis Factor (TNF) Inhibitors in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-10","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT03100253","phase":"PHASE4","title":"Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-03-01","conditions":"Rheumatoid Arthritis","enrollment":208},{"nctId":"NCT05530122","phase":"","title":"Prognosis in UC After First Biological","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2009-01","conditions":"Ulcerative Colitis","enrollment":192},{"nctId":"NCT01219257","phase":"","title":"Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting Biological Therapy","status":"COMPLETED","sponsor":"Diakonhjemmet Hospital","startDate":"2011-09","conditions":"Spondyloarthritis, Ultrasonography","enrollment":50},{"nctId":"NCT05320159","phase":"","title":"Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-03","conditions":"Psoriasis","enrollment":17743},{"nctId":"NCT04798287","phase":"","title":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-10","conditions":"Rheumatoid Arthritis","enrollment":105711},{"nctId":"NCT05405465","phase":"","title":"Effectiveness of Golimumab in Patients With Ulcerative Colitis: Results of a Real-life Study in Switzerland","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2018-01-01","conditions":"Ulcerative Colitis, Flare Up, Symptom","enrollment":103},{"nctId":"NCT04399382","phase":"","title":"A Clinical Study to Evaluate the Efficacy of Biologics in SpA","status":"UNKNOWN","sponsor":"The University of Hong Kong-Shenzhen Hospital","startDate":"2022-01-12","conditions":"Spondyloarthritis (SpA)","enrollment":40},{"nctId":"NCT04200833","phase":"","title":"Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2010-03-01","conditions":"JIA Associated Uveitis","enrollment":10},{"nctId":"NCT04378621","phase":"NA","title":"Effect of Antiinflammatory Treatment Versus Hand Training on Neuropsychiatric Comorbidity in RA-patients","status":"UNKNOWN","sponsor":"Vastra Gotaland Region","startDate":"2020-10-01","conditions":"Rheumatoid Arthritis, Pain, Fatigue","enrollment":212},{"nctId":"NCT03773445","phase":"","title":"Golimumab Trough Levels in Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Hospital San Carlos, Madrid","startDate":"2019-03-01","conditions":"Ulcerative Colitis","enrollment":52},{"nctId":"NCT03182166","phase":"PHASE2","title":"Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2017-11-21","conditions":"Ulcerative Colitis","enrollment":51},{"nctId":"NCT04772248","phase":"","title":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-22","conditions":"Rheumatoid Arthritis","enrollment":105711},{"nctId":"NCT03955861","phase":"","title":"Ultrasound Enthesitis Response in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Belfast Health and Social Care Trust","startDate":"2019-02-14","conditions":"Psoriatic Arthritis, Psoriasis, Enthesitis","enrollment":80},{"nctId":"NCT03632759","phase":"EARLY_PHASE1","title":"Targeting Beta Cell Dysfunction With Liraglutide or Golimumab in Longstanding T1D","status":"COMPLETED","sponsor":"Carla Greenbaum, MD","startDate":"2018-08-15","conditions":"Type 1 Diabetes Mellitus","enrollment":16},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT04729296","phase":"PHASE2","title":"Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D","status":"WITHDRAWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 1","enrollment":""},{"nctId":"NCT05135221","phase":"","title":"Combination Therapy With Two Biologicals","status":"COMPLETED","sponsor":"Tampere University Hospital","startDate":"2015-01-01","conditions":"IBD","enrollment":16},{"nctId":"NCT05119452","phase":"NA","title":"Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2022-03","conditions":"Rheumatoid Arthritis","enrollment":85},{"nctId":"NCT01610947","phase":"NA","title":"Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2012-05-14","conditions":"Spondyloarthritis","enrollment":398},{"nctId":"NCT03018925","phase":"","title":"Golimumab Effect in the Modulation of Gut Microbiota in Ulcerative Colitis","status":"COMPLETED","sponsor":"Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta","startDate":"2016-10","conditions":"Ulcerative Colitis","enrollment":15},{"nctId":"NCT03124121","phase":"PHASE4","title":"Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2017-09-05","conditions":"Ulcerative Colitis","enrollment":112},{"nctId":"NCT02758782","phase":"PHASE4","title":"NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2016-09","conditions":"Ankylosing Spondylitis","enrollment":156},{"nctId":"NCT02318667","phase":"PHASE4","title":"Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022).","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-02-27","conditions":"Colitis, Ulcerative","enrollment":38},{"nctId":"NCT01764321","phase":"","title":"Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":1723},{"nctId":"NCT01602302","phase":"PHASE4","title":"Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Medical University of Graz","startDate":"2012-06","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT01548768","phase":"PHASE4","title":"RHYTHM (Formerly Escape II Myocardium)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2011-10-10","conditions":"Rheumatoid Arthritis","enrollment":149},{"nctId":"NCT02065713","phase":"PHASE3","title":"Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients","status":"COMPLETED","sponsor":"Instituto de Medicina Molecular João Lobo Antunes","startDate":"2014-08","conditions":"Psoriatic Arthritis","enrollment":44},{"nctId":"NCT02755194","phase":"","title":"\"Drugs in Lactation\" Analysis Consortium","status":"TERMINATED","sponsor":"The Hospital for Sick Children","startDate":"2014-09","conditions":"Lactation","enrollment":68},{"nctId":"NCT04115423","phase":"","title":"A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab","status":"UNKNOWN","sponsor":"Sungkyunkwan University","startDate":"2020-04-01","conditions":"Infection, Rheumatoid Arthritis","enrollment":9508},{"nctId":"NCT04531423","phase":"NA","title":"PKC as Serum Biomarkers for Depression","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2020-10-01","conditions":"Major Depressive Disorder","enrollment":100},{"nctId":"NCT02011386","phase":"","title":"Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Professor Mikkel Østergaard","startDate":"2013-02","conditions":"Axial Spondyloarthritis","enrollment":53},{"nctId":"NCT04156425","phase":"NA","title":"The Role of PKC Activation in the Immune-inflammatory Mechanism of Major Depressive Depression","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2020-07-01","conditions":"Major Depressive Disorder","enrollment":180},{"nctId":"NCT02868398","phase":"","title":"Efficacy of Golimumab in Maintaining Deep Remission in UC Patients in Prolonged Remission With Infliximab","status":"COMPLETED","sponsor":"Evangelismos Hospital","startDate":"2016-06","conditions":"Ulcerative Colitis","enrollment":50},{"nctId":"NCT02728934","phase":"","title":"Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2016-02-25","conditions":"Arthritis, Rheumatoid","enrollment":1279},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"DECREASED APPETITE"},{"count":1,"reaction":"DIARRHOEA"},{"count":1,"reaction":"HEADACHE"},{"count":1,"reaction":"NAUSEA"}],"_approvalHistory":[],"publicationCount":1747,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Simponi (Golimumab)","genericName":"Simponi (Golimumab)","companyName":"Alvotech Swiss AG","companyId":"alvotech-swiss-ag","modality":"Biologic","firstApprovalDate":"","aiSummary":"Golimumab, also known as Simponi, is a TNF-alpha inhibitor used to treat various conditions, including Axial Spondyloarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriasis, and Psoriatic-arthritis. It is a monoclonal antibody that works by inhibiting the action of tumor necrosis factor, a protein involved in inflammation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}